Scarica l'app Stockscreener
27.73
1.10%
0.3005
Agios Pharmaceuticals Inc Borsa (AGIO) Ultime notizie
Agios Faces A Make-Or-Break Year As Key Drug Decisions Loom - Finimize
How The Latest Trial And FDA Risk Shift The Story For Agios Pharmaceuticals - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC (AGIO) Investigation: Bronstei - The National Law Review
Levi & Korsinsky Reminds Agios Pharmaceuticals, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities LawsAGIO - ACCESS Newswire
How Agios Pharmaceuticals Inc. (8AP) stock trades pre earningsMarket Movement Recap & Daily Profit Focused Stock Screening - Newser
Will Agios Pharmaceuticals Inc. (8AP) stock hit analyst forecasts2025 Support & Resistance & Fast Gaining Stock Reports - Newser
Why Agios Pharmaceuticals Inc. (8AP) stock stays on buy listsPortfolio Update Report & Growth Oriented Trading Recommendations - Newser
How analysts rate Agios Pharmaceuticals Inc. stock todayPortfolio Gains Report & Daily Technical Forecast Reports - Newser
Why Agios Pharmaceuticals Inc. (8AP) stock appears on watchlists2025 Historical Comparison & Real-Time Stock Entry Alerts - Newser
Why Agios Pharmaceuticals (AGIO) Is Down 7.1% After Phase 3 Sickle Cell Win With Mitapivat - Sahm
Europe Autoimmune Hemolytic Anemia Therapeutics Market to hit - openPR.com
How cyclical is Agios Pharmaceuticals Inc. (8AP) stock compared to rivalsJuly 2025 Opening Moves & Low Risk Investment Opportunities - Newser
Sickle Cell Disease Market is Predicted to Exhibit Remarkable Growth at a CAGR of 22.1% During the Forecast Period (2025–2034) Across 6MM, Owing to the Increasing Prevalence, Awareness, and Advancements in Gene Therapies | DelveInsight - GlobeNewswire Inc.
Fisher Asset Management LLC Sells 81,799 Shares of Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Is Agios Pharmaceuticals Inc. (8AP) stock a top dividend aristocrat candidateWeekly Trading Summary & Weekly Return Optimization Plans - Newser
Published on: 2025-12-03 01:52:18 - Newser
Prudential Financial Inc. Lowers Holdings in Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
How Agios Pharmaceuticals Inc. (8AP) stock gains from tech spending2025 Breakouts & Breakdowns & Fast Entry and Exit Trade Plans - Newser
Agios Pharmaceuticals (AGIO) Upgraded After Mixed Sickle Cell Data and Pending Thalassemia Catalyst - MSN
How Agios Pharmaceuticals Inc. (8AP) stock moves on employment dataMarket Risk Summary & Growth Focused Investment Plans - Newser
Published on: 2025-12-02 00:03:25 - Newser
Is Agios Pharmaceuticals Inc a good long term investmentPortfolio Risk Assessment & Minimal Capital Trading Tips - earlytimes.in
Agios Pharmaceuticals (NASDAQ:AGIO) Upgraded by Citigroup to Strong-Buy Rating - MarketBeat
How Agios Pharmaceuticals Inc. stock reacts to Fed rate cutsJuly 2025 Chart Watch & Verified Stock Trade Ideas - BỘ NỘI VỤ
How Agios Pharmaceuticals Inc. stock valuations compare to rivals2025 Biggest Moves & Long Hold Capital Preservation Tips - BỘ NỘI VỤ
A Look at Agios Pharmaceuticals (AGIO) Valuation Following Strong Phase 3 Sickle Cell Trial Results - Sahm
Envestnet Asset Management Inc. Reduces Holdings in Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Aug Intraday: How strong is Agios Pharmaceuticals Inc. stock balance sheet2025 Fundamental Recap & AI Powered Buy and Sell Recommendations - moha.gov.vn
Agios Pharmaceuticals Inc Stock Analysis and ForecastDividend Aristocrats List & Trusted Financial Advisors at No Cost - earlytimes.in
Intech Investment Management LLC Sells 12,496 Shares of Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Geode Capital Management LLC Boosts Holdings in Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Does Agios Pharmaceuticals Inc. (8AP) stock trade below intrinsic valueTreasury Yields & Stock Portfolio Risk Management - moha.gov.vn
Citigroup Initiates Coverage on AGIO with a Buy Rating | AGIO St - GuruFocus
Is Agios Pharmaceuticals Inc. stock a safe haven assetProfit Target & Long Hold Capital Preservation Plans - BỘ NỘI VỤ
(AGIO) Risk Channels and Responsive Allocation - news.stocktradersdaily.com
Agios falls after mixed data from late-stage trial for sickle cell therapy - MSN
Agios Beats Revenue Forecasts And Eyes PYRUKYND’s Future - Finimize
Agios Pharmaceuticals (NASDAQ:AGIO) Coverage Initiated at Truist Financial - MarketBeat
Why Agios Pharmaceuticals (AGIO) May See Shifting Fortunes After Strong Phase 3 Sickle Cell Data - Sahm
Truist Securities initiates coverage on Agios Pharma stock with Buy rating - Investing.com Canada
Truist Securities Initiates Coverage on Agios Pharmaceuticals (A - GuruFocus
What is HC Wainwright's Estimate for AGIO FY2025 Earnings? - MarketBeat
Can PYRUKYND's Thalassemia Review Spark A Turnaround For Agios Shares? - RTTNews
What drives Agios Pharmaceuticals Inc stock priceStock Buyback Updates & Access Powerful Market Insights - earlytimes.in
9 Oversold Biotech Stocks to Invest In - Insider Monkey
The week in pharma: action, reaction and insight – week to November 21 - The Pharma Letter
Agios rebounds as Leerink upgrades to Outperform on selloff - MSN
Agios Pharmaceuticals (NASDAQ:AGIO) Given New $20.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Why Agios Plummeted, Losing Half Its Value, While Fulcrum Surged - MSN
AGIO: JP Morgan Lowers Price Target to $20.00 -- Maintains Neutr - GuruFocus
HC Wainwright Lowers Agios Pharmaceuticals (NASDAQ:AGIO) Price Target to $48.00 - MarketBeat
Health Stocks Reveal A Mixed Bag Of Gains And Losses - Finimize
AGIO Stock Hits 52-Week Low on Mixed Sickle Cell Disease Study Results - sharewise.com
Agios Pharma stock price target lowered to $48 at H.C. Wainwright on mixed trial data - Investing.com Canada
Leerink Partners upgrades Agios Pharma stock on thalassemia potential By Investing.com - Investing.com Canada
How Recent Events Are Reshaping the Agios Pharmaceuticals Investment Story - Yahoo Finance
Agios slumps on mixed Phase III trial of mitapivat in sickle cell disease - The Pharma Letter
Will Agios Pharmaceuticals Inc. (8AP) stock beat growth indexesStock Surge & Safe Capital Allocation Plans - newser.com
1.44%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):